EP0900086A4 - Verbesserung des schlafs mittels eines die sekretion von wachstumshormonen fördernden stoffes - Google Patents

Verbesserung des schlafs mittels eines die sekretion von wachstumshormonen fördernden stoffes

Info

Publication number
EP0900086A4
EP0900086A4 EP97924576A EP97924576A EP0900086A4 EP 0900086 A4 EP0900086 A4 EP 0900086A4 EP 97924576 A EP97924576 A EP 97924576A EP 97924576 A EP97924576 A EP 97924576A EP 0900086 A4 EP0900086 A4 EP 0900086A4
Authority
EP
European Patent Office
Prior art keywords
sleep
enhancement
growth hormone
hormone secretagogue
secretagogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97924576A
Other languages
English (en)
French (fr)
Other versions
EP0900086A1 (de
Inventor
Joanne Waldstreicher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9611002.8A external-priority patent/GB9611002D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0900086A1 publication Critical patent/EP0900086A1/de
Publication of EP0900086A4 publication Critical patent/EP0900086A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EP97924576A 1996-05-07 1997-05-05 Verbesserung des schlafs mittels eines die sekretion von wachstumshormonen fördernden stoffes Withdrawn EP0900086A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1678796P 1996-05-07 1996-05-07
US16787P 1996-05-07
GB9611002 1996-05-24
GBGB9611002.8A GB9611002D0 (en) 1996-05-24 1996-05-24 Enhancement of sleep with a growth hormone secreragogue
PCT/US1997/007516 WO1997041879A1 (en) 1996-05-07 1997-05-05 Enhancement of sleep with a growth hormone secretagogue

Publications (2)

Publication Number Publication Date
EP0900086A1 EP0900086A1 (de) 1999-03-10
EP0900086A4 true EP0900086A4 (de) 2000-01-12

Family

ID=26309399

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97924576A Withdrawn EP0900086A4 (de) 1996-05-07 1997-05-05 Verbesserung des schlafs mittels eines die sekretion von wachstumshormonen fördernden stoffes

Country Status (5)

Country Link
EP (1) EP0900086A4 (de)
JP (1) JP2000511885A (de)
AU (1) AU711884B2 (de)
CA (1) CA2253390A1 (de)
WO (1) WO1997041879A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044042A1 (en) 1996-05-22 1997-11-27 Arch Development Corporation Sleep quality improvement using a growth hormone secretagogue
AU759022B2 (en) 1999-02-18 2003-04-03 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
IL143690A0 (en) * 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
IL144468A0 (en) * 2000-07-27 2002-05-23 Pfizer Prod Inc Use of growth hormone secretagogues for improvement of functional health status
JP4731031B2 (ja) * 2001-03-30 2011-07-20 株式会社デンソー 睡眠解析装置及びプログラム並びに記録媒体
WO2004080459A1 (en) * 2003-03-14 2004-09-23 Merck Sharp & Dohme Limited Method for treating mild cognitive impairment and for preventing or delaying alzheimer’s disease
WO2004108120A1 (en) * 2003-06-11 2004-12-16 Pfizer Products Inc. Use of growth hormone secretagogues for treatment of fibromyalgia
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
NZ553202A (en) 2004-08-19 2010-12-24 Vertex Pharma Modulators of muscarinic receptors
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
AU2005309365B2 (en) 2004-11-29 2011-10-06 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2006330866A1 (en) 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
KR20080094964A (ko) 2006-02-22 2008-10-27 버텍스 파마슈티칼스 인코포레이티드 무스카린성 수용체의 조절제
NZ570497A (en) 2006-02-22 2011-09-30 Vertex Pharma Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
US7858790B2 (en) 2006-06-29 2010-12-28 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2008021375A2 (en) 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2008021545A2 (en) 2006-08-18 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EA200901077A1 (ru) 2007-02-09 2010-04-30 Транзим Фарма, Инк. Макроциклические модуляторы грелинового рецептора и их применение
EP2207549A1 (de) 2007-10-03 2010-07-21 Vertex Pharmceuticals Incorporated Modulatoren muskarinischer rezeptoren

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0662481A1 (de) * 1992-12-11 1995-07-12 Merck & Co. Inc. Spiro piperidine und ihre Homolgen die die Ausschüttung von Wachstumshormonen stimulieren.
WO1996040105A1 (en) * 1995-06-07 1996-12-19 Arch Development Corporation Use of gamma-hydroxybutyrate for the stimulation of sleep-related growth hormone secretion
WO1997034604A1 (en) * 1996-03-21 1997-09-25 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5578593A (en) * 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
US5284841A (en) * 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0662481A1 (de) * 1992-12-11 1995-07-12 Merck & Co. Inc. Spiro piperidine und ihre Homolgen die die Ausschüttung von Wachstumshormonen stimulieren.
WO1996040105A1 (en) * 1995-06-07 1996-12-19 Arch Development Corporation Use of gamma-hydroxybutyrate for the stimulation of sleep-related growth hormone secretion
WO1997034604A1 (en) * 1996-03-21 1997-09-25 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, vol. 1994, 1994, Philadelphia, PA, US; abstract no. 75188, M L HARTMAN ET AL.: "Normal control of growth hormone secretion" XP002122541 *
DATABASE MEDLINE 1 January 1900 (1900-01-01), XP002122540, Database accession no. 96320058 *
G COPINSCHI ET AL.: "Effects of a 7-day treatment with a novel, orally active, growth hormone secretagogue, MK-677,on 24-hour GH profiles, insulin-like growth factor I, amd adrenocortical function in normal young men", J. CLIN. ENDOCRINOL. METABOLISM, vol. 81, no. 8, August 1996 (1996-08-01), pages 2776 - 2782 *
HORMONE RESEARCH, vol. 40, no. 1-3, 1993, Basel, pages 37 - 47 *
J TAKAHARA ET AL.: "Inhibitory effects of substance P on the gamma-aminobutyric acid and gamma-hydroxybutyric acid-induced growth hormone and prolactin release in male rats", LIFE SCIENCES, vol. 29, no. 12, 1981, UK, pages 1229 - 1233, XP000600046 *
J TAKAHARA ET AL.: "Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans", J CLIN. ENDOCRIN. METAB., vol. 44, no. 5, 1977, USA, pages 1014 - 1017, XP000600031 *
M MAMELAK ET AL.: "The effects of gamma-hydroxybutyrate on sleep", BIOLOGICAL PSYCHIATRY, vol. 12, no. 2, 1977, USA, pages 273 - 288, XP000600034 *
See also references of WO9741879A1 *

Also Published As

Publication number Publication date
WO1997041879A1 (en) 1997-11-13
EP0900086A1 (de) 1999-03-10
CA2253390A1 (en) 1997-11-13
JP2000511885A (ja) 2000-09-12
AU711884B2 (en) 1999-10-21
AU2996397A (en) 1997-11-26

Similar Documents

Publication Publication Date Title
EP0900086A4 (de) Verbesserung des schlafs mittels eines die sekretion von wachstumshormonen fördernden stoffes
AU3220097A (en) Sleep quality improvement using a growth hormone secretagogue
AU2931997A (en) Treatment of mood disorders with a growth hormone secretagogue
EP0741578A4 (de) Menschliches wachstumshormon
PL314003A1 (en) Combination of bisulphonates and substances enhancing secretion of growth hormone
IL134596A0 (en) Growth hormone secretagogues
ZA968989B (en) Polymorphic forms of a growth hormone secretagogue
EP0785784A4 (de) 4-heterocyclyl piperidine fördern die freisetzung von wachstumshormon
EP0726901A4 (de) Benzokondensierte makrocyclen die die freisetzung von wachstumshormon fördern
IL133626A0 (en) Treatment of insulin resistance with growth hormone secretagogues
HU9701277D0 (en) Process for producing parathiroide mormone-analogous and peptides connected with parathiroide hormone
GB9622440D0 (en) Treatment of congestive heart failure with a growth hormone secretagogue
GB9616700D0 (en) Hormone supplement
IL113725A0 (en) Preparing recombinant aprotini and its variants
GB9611002D0 (en) Enhancement of sleep with a growth hormone secreragogue
HK1017894A1 (en) Polymorphic forms of a growth hormone secretagogue
GB9603834D0 (en) Amorphous form of a growth hormone secretagogue
GB9609696D0 (en) Treatment of congestive heart failure with a growth hormone secretagogue
GB9614941D0 (en) Treatment of mood disorders with a growth hormone secretagogue
EP1112071A4 (de) Substanzen zur förderung der sekretion der wachstumshormone
SI0935469T1 (en) Use of growth hormone
GB9603361D0 (en) Polymorphic forms of a growth hormone secretagogue
GB9602949D0 (en) Process for the preparation of a growth hormone secretagogue
AU2419097A (en) Use of growth hormone
GB9625815D0 (en) Convergent process for the preparation of a growth hormone secretagogue

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981207

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991129

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20000620

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010102